Team, Inc. Announces Refinancing Transaction Lowers Cost of Capital and Terms Out Maturities SUGAR LAND, Texas, March 13, 2025 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering clients access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today announced that it has successfully closed on a refinancing transaction (the “Transaction”) that lowers the Company’s cost of capital and terms out its capital structure. The Transaction co...
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY ALS Plat...
LAS VEGAS--(BUSINESS WIRE)-- PLAYSTUDIOS, Inc. (Nasdaq: MYPS) (“PLAYSTUDIOS” or the “Company”), the creator of the playAWARDS loyalty platform and an award-winning developer and publisher of free-to-play mobile and social games, today announced financial results for the fourth quarter ended December 31, 2024. Andrew Pascal, Chairman and Chief Executive Officer of PLAYSTUDIOS, commented, “2024 closed with revenue and Consolidated AEBITDA in line with guidance despite continued industry pressures. More importantly, we’re entering 2025 with a more structured, cost-efficient business model geared...
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on March 3, 2025 (the “Grant Date”), ORIC granted a total of 26,450 non-qualified stock options and 4,300 restricted stock units to three new non-executive employees who began their employment with ORIC in February 2025. These inducement grants were g...
Clene to Present at the 37TH Annual Roth Conference SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings. Date: March 18, 2025Time of Presentatio...
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase 3 trial in mCRPC expected in 1H 2026; ORIC-114 registrational development plans to focus on 1L NSCLC with anticipated initiation in 2026 Favorable enrollment across both programs allows for accelerated/augmented corporate milestones,...
Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkersAPST Research data includes thousands of people living with ALS including clinical, survival, and longitudinal NfL data Clene plans to analyze the APST ALS NfL biomarker and clinical dataset to compare NfL change from its ongoing NIH-sponsored EAP to address the FDA’s request for supportive evidence of CNM-Au8’s effect on N...
LAS VEGAS--(BUSINESS WIRE)-- PLAYSTUDIOS, Inc. (Nasdaq: MYPS) (“PLAYSTUDIOS” or the “Company”), the creator of the playAWARDS loyalty platform and an award-winning developer of free-to-play mobile and social games that offer real-world rewards to players, today announced that it will release its fourth quarter and full year 2024 results after the close of the market on Monday, March 10, 2025. The Company will host a conference call and audio webcast on Monday, March 10, 2025 at 5:00 pm Eastern Time to discuss the results. To listen to the audio webcast and live Q&A, please visit the PLAYSTUD...
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts acro...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 3, 2025 (the “Grant Date”), ORIC granted a total of 29,600 non-qualified stock options and 4,800 restricted stock units to two new non-executive employees who began their employment with ORIC in January 2025. These inducement grants were g...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.